Overview As a part of our commitment to discover, develop, and deliver medicines to the patients who depend on us, we believe in supporting investigator-initiated research (IIR) to advance medical and scientific knowledge in our research areas of interest. We define IIR as unsolicited research conceived, initiated, and conducted independently of Ionis. An external investigator […]
Ionis recognizes the importance of Independent Medical Education (IME) and is committed to supporting programs that seek to advance clinical care. Ionis supports targeted high-quality accredited and non-accredited medical education programs to advance excellence in healthcare by improving disease awareness, clinical knowledge, and multidisciplinary management within our therapeutic areas of focus. IME is defined as […]
Ionis Pharmaceuticals, which recently announced it will open a sprawling research-and-development center in Oceanside, also plans a large expansion of its home base in Carlsbad.
About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis. Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build.